Teva Pharm Financials
This page shows Teva Pharm (TEVA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin repair rather than sheer sales growth drove Teva's return to profit, while deleveraging slowly improved balance-sheet resilience.
From FY2024 to FY2025, revenue rose only4.3% , but operating margin swung from-1.8% to12.5% and net income from-$1.6B to$1.4B , pointing to a profitability reset driven more by margin recovery than by simple volume growth. That rebound also turned into cash: operating cash flow reached$1.6B and free cash flow$1.1B , so the earnings improvement was not just an accounting effect.
Leverage remains the operating constraint: liabilities of
The business is not especially capex-hungry at this scale—capital spending was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Teva Pharm's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Teva Pharm has an operating margin of 12.5%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 42/100, indicating healthy but not exceptional operating efficiency. This is up from -1.8% the prior year.
Teva Pharm's revenue grew a modest 4.3% year-over-year to $17.3B. This slow but positive growth earns a score of 48/100.
Teva Pharm has elevated debt relative to equity (D/E of 4.15), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.
Teva Pharm's current ratio of 1.04 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Teva Pharm has a free cash flow margin of 6.7%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.
Teva Pharm's ROE of 17.8% shows moderate profitability relative to equity, earning a score of 35/100. This is up from -30.5% the prior year.
Teva Pharm scores 0.84, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($38.5B) relative to total liabilities ($32.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Teva Pharm passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Teva Pharm generates $1.17 in operating cash flow ($1.6B OCF vs $1.4B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Teva Pharm earns $2.4 in operating income for every $1 of interest expense ($2.2B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Teva Pharm generated $17.3B in revenue in fiscal year 2025. This represents an increase of 4.3% from the prior year.
Teva Pharm's EBITDA was $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 317.9% from the prior year.
Teva Pharm reported $1.4B in net income in fiscal year 2025. This represents an increase of 186.0% from the prior year.
Teva Pharm earned $1.21 per diluted share (EPS) in fiscal year 2025. This represents an increase of 183.4% from the prior year.
Cash & Balance Sheet
Teva Pharm generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 53.3% from the prior year.
Teva Pharm held $3.6B in cash against $0 in long-term debt as of fiscal year 2025.
Teva Pharm had 1.15B shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.
Margins & Returns
Teva Pharm's gross margin was 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.
Teva Pharm's operating margin was 12.5% in fiscal year 2025, reflecting core business profitability. This is up 14.3 percentage points from the prior year.
Teva Pharm's net profit margin was 8.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 18.1 percentage points from the prior year.
Teva Pharm's ROE was 17.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 48.3 percentage points from the prior year.
Capital Allocation
Teva Pharm invested $1.0B in research and development in fiscal year 2025. This represents an increase of 1.5% from the prior year.
Teva Pharm invested $501.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.6% from the prior year.
TEVA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0B+165.5% | $1.5B-66.5% | $4.5B+7.3% | $4.2B+7.3% | $3.9B-8.0% | $4.2B-2.4% | $4.3B+4.0% | $4.2B |
| Cost of Revenue | $2.0B | N/A | $2.2B+4.9% | $2.1B+3.0% | $2.0B-4.5% | $2.1B-3.3% | $2.2B+2.0% | $2.1B |
| Gross Profit | $2.0B | N/A | $2.3B+9.6% | $2.1B+12.0% | $1.9B-11.5% | $2.1B-1.3% | $2.1B+6.1% | $2.0B |
| R&D Expenses | $222.0M | N/A | $256.0M+4.9% | $244.0M-1.2% | $247.0M0.0% | $247.0M+2.9% | $240.0M-10.8% | $269.0M |
| SG&A Expenses | $304.0M | N/A | $317.0M+3.9% | $305.0M+2.7% | $297.0M-1.7% | $302.0M+1.3% | $298.0M+5.3% | $283.0M |
| Operating Income | $652.0M | N/A | $882.0M+93.8% | $455.0M-12.3% | $519.0M+1889.7% | -$29.0M+43.1% | -$51.0M-920.0% | -$5.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $67.0M | N/A | $214.0M+374.4% | -$78.0M-205.4% | $74.0M+155.2% | $29.0M-58.0% | $69.0M-89.0% | $630.0M |
| Net Income | $369.0M | N/A | $433.0M+53.5% | $282.0M+31.8% | $214.0M+198.6% | -$217.0M+50.3% | -$437.0M+48.3% | -$846.0M |
| EPS (Diluted) | $0.31 | N/A | $0.37+54.2% | $0.24+33.3% | $0.18 | N/A | $-0.39+48.0% | $-0.75 |
TEVA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.0B-1.7% | $40.7B+2.2% | $39.9B-0.7% | $40.1B+4.5% | $38.4B-2.3% | $39.3B-5.8% | $41.8B+1.0% | $41.3B |
| Current Assets | $13.7B-1.7% | $13.9B+9.5% | $12.7B+0.9% | $12.6B+9.5% | $11.5B-8.2% | $12.6B+1.9% | $12.3B+5.9% | $11.6B |
| Cash & Equivalents | $3.7B+5.2% | $3.6B+61.4% | $2.2B+1.9% | $2.2B+27.3% | $1.7B-48.6% | $3.3B-0.6% | $3.3B+47.0% | $2.3B |
| Inventory | $3.2B-0.1% | $3.2B-4.3% | $3.3B-5.0% | $3.5B+7.7% | $3.2B+8.0% | $3.0B-24.0% | $4.0B+0.8% | $3.9B |
| Accounts Receivable | $3.4B-8.5% | $3.7B-2.7% | $3.8B+6.9% | $3.6B+5.3% | $3.4B+10.6% | $3.1B-11.6% | $3.5B-8.1% | $3.8B |
| Goodwill | $15.8B-1.1% | $16.0B+0.3% | $15.9B0.0% | $15.9B+3.0% | $15.5B-3.3% | $16.0B-0.8% | $16.1B-2.2% | $16.5B |
| Total Liabilities | $31.8B-3.1% | $32.8B+0.7% | $32.6B-2.1% | $33.3B+3.6% | $32.1B-4.3% | $33.6B-5.0% | $35.4B+1.7% | $34.8B |
| Current Liabilities | $13.5B+0.6% | $13.5B+17.1% | $11.5B-3.1% | $11.9B+6.3% | $11.2B-12.8% | $12.8B-7.3% | $13.8B+5.8% | $13.0B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.2B+4.0% | $7.9B+9.1% | $7.3B+6.2% | $6.8B+9.0% | $6.3B+16.5% | $5.4B-11.4% | $6.1B-4.6% | $6.4B |
| Retained Earnings | -$13.4B+2.7% | -$13.8B+3.4% | -$14.2B+3.0% | -$14.7B+1.9% | -$15.0B+1.4% | -$15.2B-1.5% | -$15.0B-3.0% | -$14.5B |
TEVA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.0M-103.5% | $1.2B+213.8% | $369.0M+62.6% | $227.0M+316.2% | -$105.0M-118.3% | $575.0M-17.0% | $693.0M+572.8% | $103.0M |
| Capital Expenditures | $168.0M+18.3% | $142.0M+4.4% | $136.0M+41.7% | $96.0M-24.4% | $127.0M-1.6% | $129.0M-12.8% | $148.0M+52.6% | $97.0M |
| Free Cash Flow | -$208.0M-120.5% | $1.0B+336.1% | $233.0M+77.9% | $131.0M+156.5% | -$232.0M-152.0% | $446.0M-18.2% | $545.0M+8983.3% | $6.0M |
| Investing Cash Flow | $229.0M+38.8% | $165.0M+22.2% | $135.0M-42.8% | $236.0M+17.4% | $201.0M-0.5% | $202.0M-24.6% | $268.0M+50.6% | $178.0M |
| Financing Cash Flow | $13.0M-67.5% | $40.0M+108.8% | -$453.0M-7650.0% | $6.0M+100.3% | -$1.7B-158.8% | -$674.0M | $0+100.0% | -$966.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TEVA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.5% | N/A | 51.4%+1.1pp | 50.3%+2.1pp | 48.2%-1.9pp | 50.1%+0.6pp | 49.6%+1.0pp | 48.6% |
| Operating Margin | 16.4% | N/A | 19.7%+8.8pp | 10.9%-2.4pp | 13.3%+14.0pp | -0.7%+0.5pp | -1.2%-1.1pp | -0.1% |
| Net Margin | 9.3% | N/A | 9.7%+2.9pp | 6.8%+1.3pp | 5.5%+10.6pp | -5.1%+5.0pp | -10.1%+10.2pp | -20.3% |
| Return on Equity | 4.5% | N/A | 6.0%+1.8pp | 4.1%+0.7pp | 3.4%+7.5pp | -4.0%+3.2pp | -7.2%+6.1pp | -13.3% |
| Return on Assets | 0.9% | N/A | 1.1%+0.4pp | 0.7%+0.1pp | 0.6%+1.1pp | -0.5%+0.5pp | -1.1%+1.0pp | -2.1% |
| Current Ratio | 1.01-0.0 | 1.04-0.1 | 1.11+0.0 | 1.06+0.0 | 1.03+0.1 | 0.98+0.1 | 0.890.0 | 0.89 |
| Debt-to-Equity | 3.87-0.3 | 4.15-0.3 | 4.50-0.4 | 4.88-0.3 | 5.13-1.1 | 6.25+0.4 | 5.83+0.4 | 5.47 |
| FCF Margin | -5.2%-73.0pp | 67.7%+62.5pp | 5.2%+2.1pp | 3.1%+9.1pp | -6.0%-16.5pp | 10.5%-2.0pp | 12.6%+12.4pp | 0.1% |
Similar Companies
Frequently Asked Questions
What is Teva Pharm's annual revenue?
Teva Pharm (TEVA) reported $17.3B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Teva Pharm's revenue growing?
Teva Pharm (TEVA) revenue grew by 4.3% year-over-year, from $16.5B to $17.3B in fiscal year 2025.
Is Teva Pharm profitable?
Yes, Teva Pharm (TEVA) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 8.2%.
What is Teva Pharm's EBITDA?
Teva Pharm (TEVA) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Teva Pharm's gross margin?
Teva Pharm (TEVA) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Teva Pharm's operating margin?
Teva Pharm (TEVA) had an operating margin of 12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Teva Pharm's net profit margin?
Teva Pharm (TEVA) had a net profit margin of 8.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Teva Pharm's return on equity (ROE)?
Teva Pharm (TEVA) has a return on equity of 17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Teva Pharm's free cash flow?
Teva Pharm (TEVA) generated $1.1B in free cash flow during fiscal year 2025. This represents a 53.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Teva Pharm's operating cash flow?
Teva Pharm (TEVA) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Teva Pharm's total assets?
Teva Pharm (TEVA) had $40.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Teva Pharm's capital expenditures?
Teva Pharm (TEVA) invested $501.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Teva Pharm spend on research and development?
Teva Pharm (TEVA) invested $1.0B in research and development during fiscal year 2025.
What is Teva Pharm's current ratio?
Teva Pharm (TEVA) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.
What is Teva Pharm's debt-to-equity ratio?
Teva Pharm (TEVA) had a debt-to-equity ratio of 4.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Teva Pharm's return on assets (ROA)?
Teva Pharm (TEVA) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Teva Pharm's Altman Z-Score?
Teva Pharm (TEVA) has an Altman Z-Score of 0.84, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Teva Pharm's Piotroski F-Score?
Teva Pharm (TEVA) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Teva Pharm's earnings high quality?
Teva Pharm (TEVA) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Teva Pharm cover its interest payments?
Teva Pharm (TEVA) has an interest coverage ratio of 2.4x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Teva Pharm?
Teva Pharm (TEVA) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.